AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03405181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training with additional weight
Description: The infants will be positioned in a reclined position. A bracelet with an additional weight (20% of the total mass of the upper limb) will be placed on both wrists. The training will happen 2x/week, during 4 weeks (8 sessions). An object will be used to stimulate the reaching behavior, which will be displayed by the examiner (positioned in front of the infant), and presented in the midline at shoulder height, considering the distance from the arm's length of the infant to the height of the wrist. The physiotherapist will draw the attention of the infant to the object, moving it momentarily so that the infant perceives it and reaches it. After reaching, the object will be carefully removed and resubmitted in order to elicit a new movement. The interval between each presentation will be of approximately 5 seconds. At least 10 movements will be stimulated. If the infant does not achieve the 10 reaches within the maximum interval of 15 minutes, the session will be terminated.
Study NCT03405181 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Training without additional weight
Description: The infants will be positioned in a reclined position. A bracelet without the additional weight will be placed on both wrists. The training will happen 2x/week, during 4 weeks (8 sessions). An object will be used to stimulate the reaching behavior, which will be displayed by the examiner (positioned in front of the infant), and presented in the midline at shoulder height, considering the distance from the arm's length of the infant to the height of the wrist. The physiotherapist will draw the attention of the infant to the object, moving it momentarily so that the infant perceives it and reaches the object. After reaching, the object will be carefully removed (or picked up) and resubmitted in order to elicit a new movement. The interval between each presentation of the object will be of approximately 5 seconds. At least 10 movements will be stimulated. If the infant does not achieve the 10 reaches within the maximum interval of 15 minutes, the session will be terminated.
Study NCT02412761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.
Study NCT02412761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose
Study NCT02594943 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific Large Capacity with needle Biopsy
Description: The investigators will use a conventional biopsy forceps for taking tissue biopsies in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the conventional biopsy forceps from the tumor tissue.
Study NCT02594943 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endodrill 1A (BIBBInstruments, Lund, Sweden)
Description: The investigators will use the Endodrill, a new device for endoscopic tissue sampling in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the Endodrill instrument from the tumor tissue.
Study NCT02770365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estrace cream (Perrigo)
Study NCT02770365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estrace cream (Reference)
Study NCT02770365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Study NCT01848457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 \& 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 \& 2 of treatment Cycles 1 \& 2 (Treatment Arms 1, 3) OR Cycles 3 \& 4 (Treatment Arms 2, 4)
Study NCT01848457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate infusion duration
Description: High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours
Study NCT02412761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose
Study NCT01677039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test formulation administered with water
Description: single dose of 20 mg of test formulation with 240 mL of water
Study NCT01677039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation administered with 20% ethanol
Description: single dose of 20 mg of test formulation with 240 mL of 20% ethanol in water
Study NCT01677039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation administered with 40% ethanol
Description: single dose of 20 mg of test formulation with 240 mL of 40% ethanol
Study NCT05535036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4mg
Description: all patients had standard non-invasive monitoring including an electrocardiogram, non invasive blood pressure and pulse oxymetry. An 18-gauge intravenous cannula was inserted into the nondominant arm or hand and 500 ml of a saline solution (0.9 %) was infused. The prevention of postoperative nausea and vomiting (PONV) was assured to all patients by administering 4 mg of IV Ondansetron. Spinal anesthesia was performed according to our department protocol: L4-L5 or L3-L4 intervertebral space puncture using a 25 gauges needle, with injection of 0.5% hyperbaric Bupivacaine mixture (dose depending on patient height) associated with 2.5 ug Sufentanil and 100 ug Morphine. Before surgical incision, patients received either an intravenous injection of 8 mg (2 ml) Dexamethasone (DG) or 2 ml of a Saline solution (PG).
Study NCT05535036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients received 2ml of intravenous saline solution
Study NCT02436486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, orally, single dose
Study NCT02436486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ldalopirdine 120 mg
Description: Two 60 mg encapsulated film-coated tablets, orally, single dose
Study NCT02436486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine 360 mg
Description: Four 90 mg encapsulated film-coated tablets, orally, single dose
Study NCT02436486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Description: Encapsulated tablets, orally, single dose
Study NCT05553756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin
Description: 200 ml maltodextrin given 2 hours before cesarean section
Study NCT03067662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Study NCT02084134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone
Description: 100mg at the time of surgery
Study NCT02084134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 0.5mg every 6 hours for a total of four doses
Study NCT04892862 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCAHOİD GRAPHONAGE WITH AUTOGRAPH FROM DİSTAL RADİUS BY DORSAL APPROACH
Description: ON GENERAL OR LOCAL ANESTESİA PATİENT N SUPİNE POSTİON EFFECTED WRİST ON ARM TABLE . LISTER TUBERCULA WITH 3 CM PROXIMAL AND 3 CM DISTAL IN INCISION MADE UNDER THE SKIN. 2,3 EXTENSOR COMPARTMENTS RADIAL 4. THE EXTENSON COMPARTMENT IS EARTHED TO ULNAR A AND THE WRIST JOINT CAPSULE IS REACHED. THEN THE CAPSULE IS OPENED AND THE SCAPHOLID PROXIMAL AND MIDDLE POLE IS VIEWED. THE PERSODOARTHOSIS FIELD IS REGENERATED WITH THE TURRET AND TURR ENGINE. Following the same incision ON DISTAL UNDER RADIUS metaphyseal area of 2CM. 2X2 centimeter WINDOW opened to get spongios bone GREFt, greft added in to field of pseudoarthrosis.After scaphoid HEIGHT AND anatomy recovered it has fixated one headless mini acuttrack screw under fluoroscopy guidance .skin and subcutaneous tissue closed with non absorbabl sutures.
Study NCT04892862 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCAHOİD GRAPHONAGE WITH AUTOGRAPH FROM DİSTAL RADİUS BY VOLAR APPROACH
Description: ON GENERAL OR LOCAL ANESTESİA PATİENT N SUPİNE POSTİON EFFECTED WRİST ON ARM TABLE . İNCİSİON STARTS 2 CM RADİAL TO SCAPHOİD TUBERCULE EXTENTS ITS 3 CM PROXİMAL . AFTER PASİNG SUBCUTANEOUS TİSSUE , FCR AND RADİAL ARTERY ARE İDENTİFİED AND DİVİDED SEPERATLY THEN THE CAPSULE IS OPENED AND THE SCAPHOLID PROXIMAL AND MIDDLE POLE IS VIEWED. THE PERSODOARTHOSIS FIELD IS REGENERATED WITH THE TURRET AND TURR ENGINE. Following the same incision WİTH PASSİNG PRONATOR QUADRATUS MUSCLE , ON DISTAL UNDER 2 CENTİMETER OF RADIUS metaphyseal area . 2X2 centimeter WINDOW opened to get spongios bone GREFt, greft added in to field of pseudoarthrosis.After scaphoid HEIGHT AND anatomy recovered it has fixated one headless mini acuttrack screw under fluoroscopy guidance .skin and subcutaneous tissue closed with non absorbabl sutures.
Study NCT01010841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UltraMealPlus 360 (Medical food)
Description: Specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED)
Study NCT01010841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-glycemic-load diet
Description: Modified Mediterranean-style low-glycemic-load diet
Study NCT01010841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-glycemic-load diet
Description: Modified Mediterranean-style low-glycemic-load diet
Study NCT02664285 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: closure of subcutaneous tissue
Description: the subcutaneous fat will be closed with three to five interrupted sutures. The sutures were tied until the tissue was adequately re-approximated, but not as hard as possible to avoid necrosis after cesarean section in diabetic patients.
Study NCT02664285 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No closure of subcutaneous tissue
Description: the subcutaneous fat will not sutured after cesarean section in diabetic patients.
Study NCT04830995 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: moderate restricted diet (1800-2000 kcal/day) for four weeks
Description: high intensity interval training 3 sessions for four weeks
Study NCT03393013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KZR-616
Description: Subcutaneous Injection of KZR-616
Study NCT00872170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Participants will receive sildenafil for 12 weeks with the following therapy:~50 mg of oral sildenafil three times a day (TID) increased to 100 mg TID as tolerated in adults and children greater than 50 kg; 1 mg/kg sildenafil TID without dose escalation in children less than 50 kg
Study NCT02461485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented milk product containing Probiotics
Description: 2 pots/day during 28 days
Study NCT00948909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intervention
Study NCT00948909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: Experimental intervention
Study NCT00948909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: Active comparator intervention
Study NCT02473237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol
Description: Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
Study NCT02473237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
Study NCT04673825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient initiated care + telemonitoring
Description: See arm/group descriptions.
Study NCT04091763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol Injectable Foam
Description: Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery.
Study NCT04091763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rubber band ligation
Description: Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery.
Study NCT04898816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closure of wound using n- butyl 2-octyl cyanoacrylate tissue adhesive
Description: Application of cyanoacrylate tissue adhesives over the surgical wound
Study NCT04898816 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closure of wound using braided silk suture
Description: suturing the surgical wound using braided black silk
Study NCT04550260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab intravenous infusion
Study NCT04550260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Durvalumab matching placebo for intravenous infusion
Study NCT04550260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin + fluorouracil
Description: cisplatin + fluorouracil, as per Standard of Care
Study NCT04550260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin + fluorouracil
Description: cisplatin + fluorouracil, as per Standard of Care
Study NCT04550260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin + capecitabine
Description: cisplatin + capecitabine, as per Standard of Care
Study NCT04550260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin + capecitabine
Description: cisplatin + capecitabine, as per Standard of Care
Study NCT04550260 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 50-64Gy in total
Study NCT04550260 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation
Description: 50-64Gy in total
Study NCT03704974 — intervention group
Intervention type: BEHAVIORAL
Intervention: Video-Based Parent Training Program
Description: An18-20 week evidence-based social cognitive theory-based parenting program where parents see brief video vignettes of effective and less effective parenting and develop concepts to modify their child's behavior.
Study NCT01627340 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B vaccine
Description: 3 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Study NCT01627340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B vaccine
Description: 3 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Study NCT03513211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBA-itraconazole
Description: 150mg PO BD
Study NCT03513211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Escalating doses in Rolling 6 Phase I
Study NCT01272011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia
Description: Individuals received exposure to intermittent hypoxia for 10 days, and placebo for 1-2 days.
Study NCT01272011 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intermittent Hypoxia
Description: Individuals received exposure to intermittent hypoxia for 10 days, and placebo for 1-2 days.
Study NCT01272011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Locomotor Training
Description: Individuals received 10 days of locomotor training, intense walking training on a treadmill with body weight support. Manual assistance was provided at the legs to optimize stepping patterns.
Study NCT03416387 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3D PRINTING
Description: A 3D digital image reconstruction and a 3D printing model were performed in all patients with complex liver tumors.
Study NCT03320083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational care derived from POSSUMS
Description: Intervention group were offered a sleep education session on healthy practices for parent-baby sleep which included information on sleep needs, sleep hygiene, training in strategies to remove obstacles that get in the way of healthy sleep. Information were provided to guide the parent in forming an action plan based on cued care which included aligning the circadian clock with real time, removing the obstacles that get in the way of healthy sleep, physical activity, mindfulness, and relaxation techniques for mothers derived from the POSSUMS approach. However, we could not use Acceptance and Commitment Therapy, because none of the investigators had sufficient training on ACT at the time the study was conducted.
Study NCT01333787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Fiber Mixture
Description: During the four weeks the patients received fiber mixtures (intervention) or maltodextrine as the placebo. The fiber mixture was composed of six different types of fibers: 10.5% fructooligosaccharides, 12.5% inulin, 24% Arabic gum, 9% resistant starch, 33% Soya polysaccharide e 12% cellulose.~The dose was defined in accordance with the child's body weight: 6.3 grams of fiber supplement, which corresponds to 4.8 g of fiber, or placebo(1 table spoon) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing up to 18 kg; 12.6 grams of fiber supplement, which corresponds to 9.6 g of fiber, or placebo (2 table spoons) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing more than 18 Kg.
Study NCT01333787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Fiber Mixture
Description: During the four weeks the patients received fiber mixtures (intervention) or maltodextrine as the placebo. The fiber mixture was composed of six different types of fibers: 10.5% fructooligosaccharides, 12.5% inulin, 24% Arabic gum, 9% resistant starch, 33% Soya polysaccharide e 12% cellulose.~The dose was defined in accordance with the child's body weight: 6.3 grams of fiber supplement, which corresponds to 4.8 g of fiber, or placebo(1 table spoon) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing up to 18 kg; 12.6 grams of fiber supplement, which corresponds to 9.6 g of fiber, or placebo (2 table spoons) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing more than 18 Kg.
Study NCT05394129 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SurePath™
Description: In the liquid-based cytology, a fine-needle aspirated sample is immediately inserted into a container containing a commercially available preservative solution without a separate slide-smearing procedure and immediately after the fine-needle aspiration.
Study NCT03105765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline applied by bolus before operation started, followed by a continuous application of normal saline for 24 hours.
Study NCT03105765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Application of Ketamine 0,2mg/kg ideal Body weight by Bolus before the Operation started, followed by application of 0,2 mg/kg ideal Body weight for 24 hours.
Study NCT02461485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented Milk Product containing Probiotics + Fibers C
Description: 2 pots/day during 28 days
Study NCT02461485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented Milk Product containing Probiotics + Fibers W
Description: 2 pots/day during 28 days
Study NCT02461485 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non fermented Milk Product
Description: 2 pots/day during 28 days
Study NCT02016417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A combination of Gemcitabine and cisplatin
Description: The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
Study NCT00117442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Chemotherapy